



www.equitechcorporation.com

TSX Venture Exchange symbol: EQT

EquiTech Corporation Retains Investor Relations Firm, UMI Communications Inc.

Edmonton, Alberta, April 13, 2005 – James Chivers-Wilson, President and CEO of EquiTech Corporation (TSX-V: EQT) today announced that the company has retained the services of UMI Communications Inc. of Toronto Ontario to manage its investor relations. UMI will be focusing investor relation activities on the Ontario, Quebec and Western Canada investment communities. The UMI team directed by Jon Bridgman brings over 35 years of experience in the capital markets. EquiTech has entered into an initial contract for a period of three months at \$3,000 per month which may be extended.

UMI is pleased to be working with EquiTech to increase its visibility and awareness within the investment community, especially at this time following on the success of their recently completed Phase II clinical trial”, said Jon Bridgman, President of UMI.

EquiTech’s lead drug is a novel reformulated ibuprofen caplet, which has been designed to dissolve quickly and break apart in the stomach within minutes.

The Phase II clinical trial was undertaken because previous work done by EquiTech scientists suggested that patients in acute pain absorb drugs more slowly compared to healthy subjects not in pain. The data from the clinical study revealed that at 15 minutes after drug dosing which was the earliest time point measured; 2.8 times more ibuprofen entered the blood stream in patients who took ZAG-1701 compared to patients who took Motrin IB® (based on the ratio of the means of the area-under-the-curve calculations, a reflection of the extent of absorption). Statistically significant increased absorption in ZAG-1701 patients was also observed up to 60 minutes after taking the study medication.

The data also showed that in patients who received ZAG-1701 caplets, peak concentrations of ibuprofen in the blood stream occurred on average at 1 hour and 26 minutes compared to 2 hours and 19 minutes for Motrin IB®.

These results were supported by assessments from all patients who subjectively rated the speed and effectiveness of their pain relief using industry standard methods and questionnaires. Patients reported a trend suggesting ZAG-1701 provided faster pain relief compared to Motrin IB®.



The Phase II clinical trial was a randomized and single-blinded study designed to compare a 400mg dose of ZAG-1701 to the same dose of Motrin IB® tablets in dental patients who have undergone wisdom tooth extraction, which is the accepted industry standard test to evaluate the effectiveness of pain relief products for general mild to moderate acute pain. The pain-relieving results can be extrapolated to a variety of common acute pains. A total of 26 patients were enrolled in the trial. The trial was conducted using independent third party clinical research organizations and experts who also provided the data analysis.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction. The securities of the corporation have not been and will not be registered under the U.S. Securities Act, 1933, as amended and subject to certain exemptions may not be offered or sold in the United States or to U.S. persons. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This press release may contain forward-looking statements, i.e. information that is not strictly historical, concerning EquiTech's business and prospects. Forward-looking statements are subject to a number of risks and uncertainties. Actual events and results may differ materially from those discussed in this press release, due to factors including research, development, commercial and market risks.

For more information, please contact:

James A. Chivers-Wilson
President & Chief Executive Officer
EquiTech Corporation
780-430-1633
E-mail: james@equitechcorporation.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.